FocalTherics' Robotic HIFU Gains Access to VA, DoD Healthcare Systems for Veterans
FOCL has more than doubled off its 52-week low of $1.21.
Summary
FocalTherics has partnered with MellingMedical to make its Focal One Robotic HIFU prostate cancer treatment available to federal healthcare providers, including the VA and Department of Defense systems. This agreement leverages MellingMedical's federal supply schedule, opening a significant new market for FocalTherics' flagship product. Given the high incidence of prostate cancer among Veterans and federal initiatives to improve care, this partnership represents a material expansion of the company's addressable market and revenue potential.
At the time of this announcement, FOCL was trading at $4.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $178M. The 52-week trading range was $1.21 to $5.05. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.